Hong Kong Stock Movers: Everest Medicines (01952) Rises Over 3%; Two New Drugs Enter National Medical Insurance for the First Time, Velsipity® Shows Favorable Safety in Ulcerative Colitis Treatment

Stock News11-16

Everest Medicines (01952) rose over 3%, reaching 3.45% higher at HK$26.42 as of press time, with a turnover of HK$85.8234 million.

On the news front, on November 14, Everest Medicines' Velsipity® (etrasimod arginine tablets) and Xerava® (eravacycline hydrochloride for injection) passed the national medical insurance negotiation and were included for the first time in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2026)", with the new catalog set to take effect officially on January 1, 2027.

At the same time, its IgA nephropathy causative treatment drug Nefecon® (budesonide enteric-coated capsules) successfully renewed its contract and remains in the catalog.

With this, Everest Medicines now has three products entered into the national medical insurance catalog, covering areas such as ulcerative colitis, complicated intra-abdominal infections, and IgA nephropathy, among which Velsipity® achieved medical insurance inclusion in its first year on the market.

It is reported that Velsipity® is China's first and only approved sphingosine-1-phosphate (S1P) receptor modulator for the treatment of UC. In the largest Asian multicenter Phase III clinical study (ENLIGHT UC) conducted to date for patients with moderate-to-severe UC, Velsipity® achieved a 52-week mucosal healing rate of 51.9%, and long-term follow-up showed favorable medication safety.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment